Price
No data yet.
Social Signal Score
Analyst Ratings
7 analystsRevenue
$17.23MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Seth Lederman
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 142
- Beta
- 1.90
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -7377.99
Financials
Revenue
$17.23MNet Income
$-53.33MEBITDA
$-54.79MFree Cash Flow
$-41.68MEPS (diluted)
$-2.89Shares Outstanding (diluted)
18.44M+32681340062.3%Operating Expenses
$71.41MCash & Debt
$162.8KReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $13.11M | $-124.02M | $-14.57 |
| 2024 | $10.09M | $-130.04M | $-176.60 |
| 2023 | $7.77M | $-116.66M | $-21908.49 |
| 2022 | $0.00 | $-110.22M | $-64026.33 |
| 2021 | $0.00 | $-92.29M | $-163968.00 |
| 2020 | $0.00 | $-50.46M | $-353004.06 |
| 2019 | $0.00 | $-28.62M | $-12370558.14 |
| 2018 | $0.00 | $-29.36M | $-171596422.52 |
| 2017 | $0.00 | $-21.12M | $-202832725.18 |
| 2016 | $0.00 | $-38.84M | $-986062806.22 |
| 2015 | $0.00 | $-48.05M | $-1831605427.66 |
| 2014 | $0.00 | $-27.62M | $-1770029483.40 |
| 2013 | $0.00 | $-10.88M | $-2155717086.89 |
| 2012 | $0.00 | $-9.4K | $-3571277399.85 |
Valuation
TNXPhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
153+206.67%Social Signal Score
Mentions (14)
- Newsseekingalpha.com·13d ago·Positive
Tonix Pharmaceuticals Holding Corp. (TNXP) Q3 2026 Earnings Call Transcript Tonix Pharmaceuticals Holding Corp. (TNXP) Q3 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·13d ago·Negative
What Tonix Pharmaceuticals (TNXP) Said on Its Q3 Earnings Call Tonix Pharmaceuticals NASDAQ: TNXP reported approximately $15 million in third-quarter sales of its fibromyalgia drug TONMYA, up 37% from the previous quarter, as insurance coverage expanded and prescriptions increased.
View source ↗ - Newsglobenewswire.com·13d ago·Neutral
Tonix Pharmaceuticals Reports Third Quarter 2026 Financial Results and Operational Highlights Third quarter TONMYA® net sales of approximately $15 million, up 37% from the second quarter Approximately $163 million in cash and cash equivalents as of September 30, 2026 Strategic focus on supporting TONMYA growth and advancing core clinical programs Conference call today at 8:30 a.m. ET BERKELEY HEIGHTS, N.J.
View source ↗ - Newsglobenewswire.com·18d ago·Neutral
Tonix Pharmaceuticals to Present at Guggenheim's 3rd Annual Healthcare Innovation Conference BERKELEY HEIGHTS, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or “the Company”), a fully integrated, commercial-stage biopharmaceutical company, today announced that management will present and host 1x1 meetings at Guggenheim's 3rd Annual Healthcare Innovation Conference in Boston, Massachusetts on Tuesday, November 10, 2026.
View source ↗ - Newsglobenewswire.com·20d ago·Neutral
Tonix Pharmaceuticals Appoints George Lederman, Ph.D., as Executive Vice President of Strategy and Transformation BERKELEY HEIGHTS, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial-stage biopharmaceutical company, today announced the appointment of George Lederman, Ph.D.
View source ↗ - Newsglobenewswire.com·26d ago·Negative
… years approved by the U.S. Food and Drug Administration (FDA) BERKELEY HEIGHTS, N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial-stage biopharmaceutical company, presented data from an analysis of the Phase 3 RELIEF and RESILIENT studies of TONMYA® (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults demonstrating outcomes as measured by the Fibromyalgia Impact Qu…
View source ↗ - Newsglobenewswire.com·27d ago·Neutral
Tonix Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 9, 2026 BERKELEY HEIGHTS, N.J., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial-stage biotechnology company, today announced that it will host a conference call and webcast to report third quarter 2026 financial results and operational highlights on Monday, November 9, 2026, at 8:30 a.m.
View source ↗ - Newsglobenewswire.com·34d ago·Neutral
…hase 3 Data on TONMYA® at the IASP 2026 World Congress on Pain BERKELEY HEIGHTS, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial-stage biopharmaceutical company, today announced a poster examining the effects of TONMYA® (cyclobenzaprine HCl sublingual tablets) on fibromyalgia symptoms and physical function will be presented at the International Association for the Study of Pain (IASP) 2026 World…
View source ↗ - Newsglobenewswire.com·38d ago·Neutral
… Announces Presentations at World Vaccine Congress Europe 2026 BERKELEY HEIGHTS, N.J., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or “the Company”), a fully integrated, commercial-stage biopharmaceutical company, today announced an oral presentation on TNX-801, a live, attenuated, minimally replicative investigational vaccine platform based on horsepox virus to protect against mpox and other infectious diseases, and a working group session led b…
View source ↗ - Newsglobenewswire.com·61d ago·Negative
…oximately 166 million covered lives (53% of total U.S. lives) BERKELEY HEIGHTS, N.J., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or “the Company”), a fully integrated, commercial-stage biopharmaceutical company, today announced a second major managed Medicare agreement for TONMYA® (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults that is effective immediately, adding approximately 21 million Medicare lives (38…
View source ↗ - Newsmarketbeat.com·72d ago·Neutral
Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears Tonix Pharmaceuticals NASDAQ: TNXP CEO Seth Lederman told attendees at the Cantor Healthcare Conference that the company's near-term focus is the commercial launch of TONMYA, its FDA-approved treatment for fibromyalgia in adults, while it advances development programs in Lyme disease prevention and transplant rejection.
View source ↗ - Newsmarketbeat.com·96d ago·Neutral
Tonix Pharmaceuticals Highlights TONMYA Sales Surge, Lyme and Depression Pipeline Tonix Pharmaceuticals NASDAQ: TNXP is focusing its near-term strategy on the commercial launch of TONMYA for fibromyalgia while advancing development programs in Lyme disease prevention and major depressive disorder, Chief Executive Officer Seth Lederman said during a Canaccord Genuity conference presentation.
View source ↗ - Newsseekingalpha.com·104d ago·Positive
Tonix Pharmaceuticals Holding Corp. (TNXP) Q2 2026 Earnings Call Transcript Tonix Pharmaceuticals Holding Corp. (TNXP) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·104d ago·Neutral
Tonix Pharmaceuticals Q2 Earnings Call Highlights Tonix Pharmaceuticals NASDAQ: TNXP reported second-quarter 2026 net product revenue of approximately $13.5 million, led by $11 million in sales of fibromyalgia treatment Tonmya. The company said Tonmya sales rose 197% from the first quarter, its second full quarter of commercial sales following the product's November launch.
View source ↗
Earnings
Thu, Mar 11(in 4 months)
Consensus estimate $-2.34 per share
Typical surprise -18.1% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Nov 9$-2.89 vs $-2.39miss
- Mon, Aug 10$-2.44 vs $-2.64beat
- Mon, May 11$-2.93 vs $-2.54miss
- Thu, Mar 12$-3.98 vs $-3.16miss
- Mon, Nov 10$-3.59 vs $-3.59beat
- Tue, Aug 12$-3.86 vs $-3.10miss
Estimates and results for TNXP via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TNXP officers and directors.
- Bought
- $589k
- Sold
- —
11 trades
0 trades
- Lederman Sethbought
- Lederman Sethbought
- Bagger Richard Hbought
- Taylor Carolyn E.bought
- Lederman Sethbought
- Stillwell Richard Newcombbought
- Lederman Sethbought
- Lederman Sethbought
89 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in TNXP.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
